Skip to content
Artwork for NB Hot Topics Podcast
NB Hot Topics Podcast · Apr 11, 2025 · 28 min

S6 E9: Interview with Dr Stephen Bradley on CXR rates in GP & lung cancer; orthostatic HYPERtension; overactive bladder tests

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we are joined by Dr Stephen Bradley, lead author of a new paper published in the BJGP looking at rates of CXR use in general practice and how this influences lung cancer stage at diagnosis and mortality. He discusses the findings of his research and how this might influence our practice. In other research, we look at a new paper in the BMJ on orthostatic HYPERtension - yes, you read that correctly - does treatment help, and does it really matter in the first place? And from the Lancet, research looking at the role of urodynamic studies in women with refractory overactive bladder - does it improve outcomes, or should it be stopped? References BMJ Orthostatic hypertension and BP treatment BMJ OH editorial Lancet Refractory overactive bladder & urodynamic studies BJGP CXR in GP & lung cancer staging and mortality www.nbmedical.com/podcast

0:00-28:55

transcript

No transcript — this publisher did not publish one.

show notes

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we are joined by Dr Stephen Bradley, lead author of a new paper published in the BJGP looking at rates of CXR use in general practice and how this influences lung cancer stage at diagnosis and mortality

He discusses the findings of his research and how this might influence our practice. 

In other research, we look at a new paper in the BMJ on orthostatic HYPERtension - yes, you read that correctly - does treatment help, and does it really matter in the first place? And from the Lancet, research looking at the role of urodynamic studies in women with refractory overactive bladder - does it improve outcomes, or should it be stopped?

References

BMJ Orthostatic hypertension and BP treatment

BMJ OH editorial

Lancet Refractory overactive bladder & urodynamic studies

BJGP CXR in GP & lung cancer staging and mortality

www.nbmedical.com/podcast

links4